Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Clears VisionBlue For Use In Ophthalmic Surgery

This article was originally published in The Pink Sheet Daily

Executive Summary

Dutch Ophthalmic’s VisionBlue is the first product approved for staining the anterior lens capsule during cataract surgery, FDA says. Safety and effectiveness of trypan blue ophthalmic solution were established in pediatric patients; no differences have been observed between elderly and younger patients.

You may also be interested in...



Dutch Ophthalmic’s VisionBlue Detailing Will Cite Sterility Problems With Compounded Versions

Custom Rx Compounding Pharmacy issues a nationwide recall of all unexpired syringes of trypan blue 0.06% ophthalmic solution following two reports of vision loss.

Dutch Ophthalmic’s VisionBlue Detailing Will Cite Sterility Problems With Compounded Versions

Custom Rx Compounding Pharmacy issues a nationwide recall of all unexpired syringes of trypan blue 0.06% ophthalmic solution following two reports of vision loss.

VisionBlue Ad, Website Omit Risk Information, FDA Warning Letter Says

Dutch Ophthalmic has posted a disclaimer on its website and plans to run corrective ads in response to the citation for failing to include risk information in marketing materials for the staining agent. WLF's "DDMAC Watch" is challenging FDA's warning letter on VisionBlue.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel